NeoGenomics NEO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 43.2%-1.1pp | 43.2%-0.7pp | 43.5%-0.1pp | 43.9%+1.3pp | 44.3%+2.5pp | |
| Operating margin | -14.2%-1.0pp | -15.9%-2.0pp | -17%-2.7pp | -16.7%-1.5pp | -13.3%+3.6pp | |
| Net margin | -13.3%-1.8pp | -14.9%-2.9pp | -16%-3.9pp | -15.1%-2.6pp | -11.5%+2.3pp | |
| Returns | ||||||
| Return on equity | -11.6%-3.0pp | -12.4%-3.9pp | -13%-4.6pp | -11.8%-3.4pp | -8.6%+0.3pp | |
| Return on invested capital | -15.7%-1.6pp | -15%-2.5pp | -17.8%-3.9pp | -16.5%-2.5pp | -14.1%+0.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.4×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.4×+2.4× | 4.3×+2.3× | 3.9×+1.9× | 3.9×+1.9× | 2.1×-5.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.2× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $6.42-8.0% | $6.53-8.3% | $6.53-8.7% | $6.67-7.9% | $6.97-4.8% | |
| Valuation | ||||||
| Market capitalization | $963.21M-21.0% | $1.52B-28.1% | $997.26M-46.5% | $930.46M-46.8% | $1.22B-38.5% | |
| Price / sales | 1.3×-0.5× | 2.1×-1.1× | 1.4×-1.5× | 1.4×-1.4× | 1.8×-1.4× | |
| Price / book | 1.2×-0.2× | 1.8×-0.5× | 1.2×-0.9× | 1.1×-0.8× | 1.4×-0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NeoGenomics's profit margins?
- NeoGenomics (NEO) runs a 43.2% gross margin and a -14.2% operating margin, with a -13.3% net margin.
- Where do NeoGenomics's ratios come from?
- Every ratio is computed from NeoGenomics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
